rosiglitazone has been researched along with Hyperlipemia in 34 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (2.94) | 18.2507 |
2000's | 22 (64.71) | 29.6817 |
2010's | 11 (32.35) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
Bajji, AC; Chakrabarti, R; Juluri, S; Kalchar, S; Lohray, BB; Lohray, VB; Mamidi, NV; Misra, P; Padakanti, S; Poondra, RR; Rajagopalan, R; Vikramadithyan, RK | 1 |
Biller, SA; Cap, M; Chandrasena, G; Chang, SY; Chen, S; Cheng, L; Cheng, PT; Devasthale, PV; Doweyko, A; Farrelly, D; Golla, R; Grover, G; Hariharan, N; Harrity, T; Humphreys, WG; Jeon, Y; Ma, Z; Moore, L; Qu, F; Ren, J; Ryono, DE; Sasseville, VG; Seethala, R; Selan, F; Shao, C; Sleph, P; Sun, W; Tieman, A; Wang, W; Wetterau, JR; Zhang, H | 1 |
Berger, JP; Doebber, TW; Forrest, MJ; Jones, AB; Liu, K; Macnaul, KL; Moller, DE; Xu, L; Zhou, G | 1 |
Bullock, WH; Burns, M; Chen, L; Claus, T; Daly, M; Dela Cruz, FE; Ehrgott, FJ; Johnson, JS; Livingston, JN; Ma, X; Majumdar, D; Rudolph, J; Schoenleber, RW; Shapiro, J; Tsutsumi, M; Yang, L | 1 |
Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS | 1 |
Aragonès, G; Beltrán-Debón, R; Camps, J; García-Heredia, A; Geeraert, B; Holvoet, P; Joven, J; Pedro-Botet, J; Rodríguez-Gallego, E; Rull, A | 1 |
Kuo, YH; Lin, CH; Shih, CC | 1 |
Ji, K; Wang, H; Wang, R; Wu, X; Yan, Z; Zang, B | 1 |
Ho, HY; Jian, JY; Lin, CH; Shih, CC; Wu, JB | 1 |
Du, X; Gao, M; Li, L; Liao, J; Liu, G; Qi, Y; Wang, M; Wang, Y; Yang, H | 1 |
Gaikwad, AB; Pathan, AR; Ramarao, P; Viswanad, B | 1 |
Distrutti, E; Fiorucci, S; Mencarelli, A; Renga, B | 1 |
Srivastava, RA | 2 |
Zhou, JY; Zhou, SW | 1 |
Cabezas, MC; Dallinga-Thie, G; de Koning, EJ; Hoepelman, AI; Rabelink, TJ; van Wijk, JP | 1 |
Chang, B; Chen, L; Dong, L; Li, M; Li, XY; Lian, FM; Liu, WK; Qin, PJ; Tong, XL; Wang, J; Yu, B; Zhang, JH; Zhen, Z | 1 |
Feng, Y; Ruan, KF; Wang, LY; Wang, S; Wang, Y; Xu, DS | 1 |
Viberti, GC | 1 |
Acerini, CL; Agostini, M; Bell, JD; Boiani, R; Chatterjee, VK; Cinti, S; Dixon, AK; Dunne, F; Gurnell, M; Jebb, SA; Karpe, F; O'Rahilly, S; Savage, DB; Tan, GD; Thomas, EL; Umpleby, AM; Vidal-Puig, A; Williams, RL | 1 |
Chilton, RJ; Stolar, MW | 1 |
Henry, RR | 1 |
Kiselevich, A; London, D; Magen, E; Priluk, R; Viskoper, RJ; Volchek, L; Yosefy, C | 1 |
Collins, JN; Gee, MK; Kauffman, RF; Rankin, SE; Wagner, JD; Zhang, L | 1 |
Gavrilova, O; Haluzik, M; Kim, H; LeRoith, D; Pajvani, UB; Portas, J; Scherer, PE; Sun, H; Yakar, S | 1 |
Barr, R; Bensch, WR; Brozinick, JT; Bull, C; Dana, S; Hawkins, E; Klausing, K; Martin, JA; Otto, K; Rafaeloff-Phail, R; Rafizadeh-Montrose, C; Reifel-Miller, A; Rhodes, G; Robey, R; Rojo, I; Rungta, D; Snyder, D; Warshawsky, A; Wilbur, K; Zhang, T; Zink, R | 1 |
Mukhtar, R; Reckless, JP | 1 |
Buse, JB; Deeg, MA; Goldberg, RB; Jacober, SJ; Kendall, DM; Khan, MA; Perez, AT; Pinaire, JA; Tan, MH; Zagar, AJ | 1 |
Biller, S; Cap, M; Chen, S; Cheng, PT; Chu, C; Devasthale, P; Farrelly, D; Fenderson, W; Gregg, R; Gu, L; Hariharan, N; Harrity, T; Jeon, Y; Kunselman, L; Mookhtiar, KA; Ponticiello, R; Qu, F; Ren, J; Ryono, D; Seethala, R; Shao, C; Tieman, A; Wang, W; Wetterau, J; Yang, WP; Zhang, H; Zhou, M | 1 |
Albert, AJ; Cong, Z; Gabbay, RA; Gilliland, KL; Liu, W; Mauger, DT; Nelson, AM; Rosamilia, LL; Sivarajah, S; Thiboutot, DM; Trivedi, NR | 1 |
Vergès, B | 1 |
Abram, SR; Carter, C; Dearman, J; Hester, RL; Xiang, L | 1 |
Chinetti, G; Delerive, P; Fadel, A; Fruchart, JC; Habib, A; Koenig, W; Lebret, M; Maclouf, J; Merval, R; Najib, J; Staels, B; Tedgui, A; Torra, IP | 1 |
6 review(s) available for rosiglitazone and Hyperlipemia
Article | Year |
---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hemodynamics; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2003 |
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2003 |
Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone.
Topics: Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hyperlipidemias; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2005 |
Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypoglycemic Agents; Lipids; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
4 trial(s) available for rosiglitazone and Hyperlipemia
Article | Year |
---|---|
Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy.
Topics: Area Under Curve; Biomarkers; Cholesterol; Fatty Acids, Nonesterified; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxybutyrates; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Netherlands; Postprandial Period; Prospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; Triglycerides | 2011 |
Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
Topics: Administration, Oral; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, LDL; Cilazapril; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Evoked Potentials; Female; Glyburide; Glycated Hemoglobin; Heart Rate; Humans; Hyperlipidemias; Hypertension; Insulin; Insulin Resistance; Kidney; Male; Rosiglitazone; Simvastatin; Skin Physiological Phenomena; Sympathetic Nervous System; Thiazolidinediones; Time Factors; Ultrasonography; Vasodilation | 2004 |
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
Topics: Aged; Apolipoproteins B; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Placebos; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
Peroxisome proliferator-activated receptors increase human sebum production.
Topics: Adult; Cell Line, Transformed; Diabetes Mellitus; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Isotretinoin; Ligands; Lipogenesis; Male; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Sebaceous Glands; Sebum; Thiazolidinediones | 2006 |
24 other study(ies) available for rosiglitazone and Hyperlipemia
Article | Year |
---|---|
(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity.
Topics: Animals; Biological Availability; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Mice; Oxazines; Phenylpropionates; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Transcription Factors; Triglycerides | 2001 |
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and
Topics: Adipocytes; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids; Glycine; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Obese; Oxazoles; PPAR alpha; PPAR gamma; Transcriptional Activation; Triglycerides | 2005 |
Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Carrier Proteins; Chlorocebus aethiops; Cholesterol; COS Cells; Diabetes Mellitus, Type 2; Dogs; Fatty Acid-Binding Proteins; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Isoxazoles; Mice; Mice, Obese; PPAR alpha; PPAR gamma; Propionates; Radioligand Assay; RNA, Messenger; Structure-Activity Relationship; Transcriptional Activation; Triglycerides; Weight Gain | 2005 |
Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.
Topics: Acetates; Animals; Apolipoprotein A-I; Cell Line; Cricetinae; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; In Vitro Techniques; Indans; Lipids; Male; Mice; Mice, Transgenic; PPAR alpha; PPAR delta; PPAR gamma; Radioligand Assay; Rats; Rats, Zucker; Solubility; Stereoisomerism; Structure-Activity Relationship; Transcriptional Activation; Triazoles | 2007 |
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult | 2017 |
Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study.
Topics: Animals; Disease Models, Animal; Fatty Liver; Fenofibrate; Gene Expression Profiling; Gene Expression Regulation; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Metabolome; Mice; Mice, Transgenic; Obesity; Peroxisome Proliferator-Activated Receptors; Protein Interaction Mapping; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcriptome | 2014 |
Effects of Bofu-Tsusho-San on diabetes and hyperlipidemia associated with AMP-activated protein kinase and glucose transporter 4 in high-fat-fed mice.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diet, High-Fat; Down-Regulation; Drugs, Chinese Herbal; Fatty Acid Synthases; Gluconeogenesis; Glucose Transporter Type 4; Hyperlipidemias; Liver; Male; Mice; Mice, Inbred C57BL; Phosphorylation; PPAR alpha; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones | 2014 |
Rosiglitazone attenuates renal injury caused by hyperlipidemic pancreatitis.
Topics: Acute Kidney Injury; Animals; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Hyperlipidemias; Hypoglycemic Agents; Immunohistochemistry; In Situ Nick-End Labeling; Male; Pancreatitis; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones | 2015 |
(-)-Epicatechin-3-O-β-D-allopyranoside from Davallia formosana, Prevents Diabetes and Hyperlipidemia by Regulation of Glucose Transporter 4 and AMP-Activated Protein Kinase Phosphorylation in High-Fat-Fed Mice.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fenofibrate; Hyperlipidemias; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Phosphorylation; Plants, Medicinal; Rosiglitazone; Thiazolidinediones | 2015 |
Adipose tissue deficiency results in severe hyperlipidemia and atherosclerosis in the low-density lipoprotein receptor knockout mice.
Topics: Adipose Tissue; Adiposity; Animals; Atherosclerosis; Cholesterol; Diet, High-Fat; Disease Models, Animal; Genetic Predisposition to Disease; GTP-Binding Protein gamma Subunits; Heterotrimeric GTP-Binding Proteins; Hyperlipidemias; Hypolipidemic Agents; Macrophages; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Receptors, LDL; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Time Factors | 2016 |
Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats.
Topics: Animals; Behavior, Animal; Blood Glucose; Cognition; Dietary Fats; Disease Models, Animal; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Maze Learning; Memory; Motor Activity; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Time Factors | 2008 |
Antiatherosclerotic effect of farnesoid X receptor.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cardiovascular Agents; CD11b Antigen; CD36 Antigens; Chenodeoxycholic Acid; Disease Models, Animal; DNA-Binding Proteins; Female; Humans; Hyperlipidemias; Interleukin-1beta; Interleukin-6; Ligands; Lipids; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR gamma; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Toll-Like Receptor 4; Transcription Factors; Tumor Necrosis Factor-alpha | 2009 |
Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diacylglycerol O-Acyltransferase; DNA-Binding Proteins; Down-Regulation; Drug Interactions; Fenofibrate; Hydrocarbons, Fluorinated; Hyperlipidemias; Hypolipidemic Agents; Liver X Receptors; Male; Mice; Orphan Nuclear Receptors; Phosphoenolpyruvate Carboxykinase (GTP); PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sulfonamides; Thiazolidinediones; Triglycerides | 2009 |
Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver.
Topics: Animals; Antioxidants; Berberine; Coptis; Cyclin T; Cyclin-Dependent Kinase 9; Diabetes Mellitus, Experimental; Diet; Drugs, Chinese Herbal; Enzymes; Fenofibrate; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Peroxidation; Liver; Male; Malondialdehyde; Phytotherapy; Positive Transcriptional Elongation Factor B; Rats; Rats, Wistar; Rhizome; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Up-Regulation | 2011 |
Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cricetinae; Fatty Acids; Female; Fenofibrate; Hydrocarbons, Fluorinated; Hyperlipidemias; Liver X Receptors; Male; Mesocricetus; Orphan Nuclear Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Sulfonamides; Thiazolidinediones; Triglycerides | 2011 |
Anti-diabetic effects of a Coptis chinensis containing new traditional Chinese medicine formula in type 2 diabetic rats.
Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Area Under Curve; Blood Glucose; Bupleurum; Coptis; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Glucose Tolerance Test; Glucose Transporter Type 4; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipid Metabolism; Lipids; Muscle, Skeletal; Phytotherapy; Rats; Rats, Inbred OLETF; Rheum; Rosiglitazone; Scutellaria baicalensis; Thiazolidinediones | 2011 |
MDG-1, a polysaccharide from Ophiopogon japonicus exerts hypoglycemic effects through the PI3K/Akt pathway in a diabetic KKAy mouse model.
Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Experimental; Female; Glucose Tolerance Test; Glucose Transporter Type 4; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hyperglycemia; Hyperinsulinism; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Mice, Inbred C57BL; Ophiopogon; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Plant Roots; Polysaccharides; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazolidinediones; Triglycerides | 2012 |
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
Topics: Abdomen; Adipose Tissue; Adult; Body Composition; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Fatty Acids, Nonesterified; Fatty Liver; Female; Gene Expression; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Liver; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; Mutation; Neoplasm Proteins; Phenotype; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Tumor Suppressor Proteins | 2003 |
Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.
Topics: Animals; Biomarkers; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Hyperlipidemias; Hypoglycemic Agents; Insulin; Lipids; Macaca fascicularis; Male; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Characteristics; Thiazolidinediones; Transcription Factors; Triglycerides; Tumor Necrosis Factor-alpha | 2004 |
Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Transgenic; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2004 |
A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Topics: Adiponectin; Alkynes; Animals; Binding, Competitive; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Cinnamates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fenofibrate; Gene Expression Regulation, Enzymologic; Glucose; Homozygote; Humans; Hyperlipidemias; In Vitro Techniques; Insulin; Intercellular Signaling Peptides and Proteins; Kinetics; Lipid Metabolism; Liver; Male; Mice; Mice, Transgenic; Models, Chemical; PPAR alpha; PPAR gamma; Protein Binding; Protein Isoforms; Rats; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transfection; Triglycerides; Two-Hybrid System Techniques | 2005 |
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Corticosterone; Diabetes Mellitus, Type 2; Diet; Female; Glycine; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liver; Mice; Obesity; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2006 |
Insulin resistance and impaired functional vasodilation in obese Zucker rats.
Topics: Animals; Antioxidants; Arachidonic Acid; Arterioles; Blood Glucose; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Disease Models, Animal; Electric Stimulation; Fatty Acids, Unsaturated; Hydrazines; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin Resistance; Kidney Cortex; Male; Muscle, Skeletal; NADPH Oxidases; Obesity; Oxidative Stress; Rats; Rats, Zucker; Receptors, Thromboxane; Rosiglitazone; Spin Labels; Superoxides; Thiazolidinediones; Thromboxanes; Time Factors; Triglycerides; Vasoconstriction; Vasodilation | 2008 |
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Enzymologic; Humans; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Interleukin-1; Interleukin-6; Isoenzymes; Membrane Proteins; Muscle, Smooth, Vascular; NF-kappa B; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 1998 |